This analysis ignores the issue of negative side effects. The most serious, rhabdomyolysis, occurs in about 0.1% of those taking statins. Liver issues are more common, and the cost of monitoring that might affect the cost/benefit ratio.

It would be nice to have a next generation statin that didn't have the muscle side effect (which appears to be independent of the primary mode of action of statins.)

1. Dietary Cholesterol and the Lack of Evidence in Cardiovascular Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6024687/

2, Doubt cast on wisdom of targeting ‘bad’ cholesterol to curb heart disease risk

British Medical journal

  https://bmjgroup.com/doubt-cast-on-wisdom-of-targeting-bad-cholesterol-to-curb-heart-disease-risk/

Setting targets for ‘bad’ (LDL) cholesterol levels to ward off heart disease and death in those at risk might seem intuitive, but decades of research have failed to show any consistent benefit for this approach, reveals an analysis of the available data, published online in BMJ Evidence Based Medicine.

The cholesterol panic is great for big pharma and the millions they make prescibing Statins.

For 20 + years I have lived on a high fat diet with 70% of my calories from fats.

My cholesterol has been quite normal